Scandinavian ChemoTech has announced the early publication of an independent clinical abstract ahead of the ECVS congress (July 9–11).
Scandinavian ChemoTech announced a 6MSEK growth loan from a major Swedish financial institution.
Redeye provides an update following Scandinavian Chemotech’s Q1 2026 report.
Redeye provides an initial take on Scandinavian ChemoTech’s Q1 2026 report.
CEO Mohan Frick and Chairman Robin Sukhia discuss the company’s proposed restructuring, the Nasdaq verdict, and what the split into Animal C...
Yesterday, Scandinavian ChemoTech reported its best-ever Q1, with Animal Care sales of USD299k (~SEK2.
A directed issue of SEK2.55m, settled via debt offset by insiders, provides some balance sheet relief.
Redeye comments on Scandinavian Chemotech announcing that its subsidiary Scandinavian Meditech has received a full CDSCO MD-15 import licens...
Redeye comments on ChemoTech’s announcement that a clinical study evaluating its TSE technology for the treatment of equine sarcoids (tumour...
Redeye provides an update on Scandinavian ChemoTech following the Q4 2025 report.
Redeye provides an initial comment on Scandinavian ChemoTech’s Q4 2025 report.
Redeye provides an update on Scandinavian ChemoTech following the Q3 2025 report.
Redeye provides an initial comment on Scandinavian ChemoTech’s Q3 2025 report.
Redeye provides a short comment on the recently announced Q3 sales figure from Scandinavian ChemoTech.
Redeye provides an update on Scandinavian ChemoTech following the Q2 2025 report.
Redeye provides an initial take on the Q2 2025 report from Scandinavian ChemoTech.
Redeye provides a short comment on the recently announced directed issue from Scandinavian ChemoTech.
Redeye provides a short comment on Scandinavian ChemoTech announcing sales of USD390k in the second quarter.
Redeye provides an update on Scandinavian ChemoTech following the Q1 2025 report.
Redeye gives its initial comments on the Q1 2025 report from Scandinavian ChemoTech, which was mostly in line with our estimates.
Redeye provides a brief comment on Scandinavian ChemoTech's order intake for April, announced early in the morning yesterday.
Redeye provides a short comment on today's order announcement from Scandinavian ChemoTech, this is the second, rather significant, order wit...
Redeye provides a comment on Scandinavian ChemoTech's recently announced collaboration with a global operator of equine hospitals.
Redeye provides an update on Scandinavian ChemoTech following the Q4 2024 report.
Redeye gives its initial comments on the Q4 2024 report from Scandinavian ChemoTech, which was mostly in line with our estimates for operati...
Redeye provides a comment on today's news from Scandinavian Chemotech, where the company announced that the Animal Care segment, on a standa...
Redeye provides a comment on today's news in Scandinavian ChemoTech regarding the separation of Human Care and Animal Care into two entities...
Redeye provides an update on Scandinavian ChemoTech following the Q3 2024 report.
Redeye gives its initial comments on the Q3 2024 report from Scandinavian ChemoTech, which was mostly in line with our estimates.
Redeye provides an update on Scandinavian ChemoTech following the Q2 2024 report.
Redeye provides its initial comments on the Q2 2024 report from Scandinavian Chemotech, which was mostly in line with estimates.
Redeye provides a comment on the outcome in Scandinavian ChemoTech’s rights issue.
Redeye provides its initial comments on Scandinavian ChemoTech's rights issue announced this morning.
Redeye provides a short research note following Scandinavian ChemoTech's anouncement of its first order in the Canadian market.
Redeye provides an update on Scandinavian ChemoTech following the strong Q1 2024 report.
Redeye provides its initial comments on the Q1 2024 report from Scandinavian Chemotech, which was broadly above our expectations.
Redeye provides a short comment on Scandinavian ChemoTech's EUR48k order from a Belgian equine (horse) clinic announced this afternoon.
Redeye provides a research update on Scandinavian ChemoTech following the Q4 2023 report and the retracted sales target in India.
Redeye provides its initial comments on the Q4 2023 report from Scandinavian Chemotech.
Redeye provides its comments on Scandinavian ChemoTech’s press release from earlier today.
Redeye is encouraged to see the progress made by Scandinavian ChemoTech in the Q3 2023 report, which showed increasing sales and better than...
Redeye provides an initial comment on the Q3 2023 report from Scandinavian ChemoTech.
Redeye comments on Scandinavian ChemoTech’s preferred rights issue announced earlier today.
Redeye comments on the news that Scandinavian ChemoTech has signed a commercial contract with Asirvatham Speciality Hospital in Madurai, Ind...
Redeye comments on Scandinavian ChemoTech’s distribution agreement with Lambertis Corporation AS in Chile.
Redeye comments on Scandinavian ChemoTech's strategy update.
Redeye comments on Scandinavian ChemoTech’s latest supplier contract with MedVet Group and the initial order of SEK1.
Redeye leaves its comments on Scandinavian ChemoTech following the company’s Q1 2023 report.
Redeye comments on Scandinavian ChemoTech’s TO3 exercise, which generated SEK7.
Over the past week, several noteworthy events have occurred while Scandinavian Chemotech’s TO3 moves towards the end of its subscription per...
Redeye initiates coverage of Scandinavian ChemoTech, a Swedish medtech company in early-stage commercialisation with its tumour-specific ele...
ChemoTech är ett svenskt medicinteknikföretag med säte i Lund, som utvecklat ett nytt behandlingsalternativ för människor och djur med cance...
Sammanfattning av kvartalet Bolaget hade en nettoomsättning om 9 KSEK (41) under tredje kvartalet 2021.
